Status:
COMPLETED
Lung Cancer Symptom Assessment and Management Intervention
Lead Sponsor:
Dana-Farber Cancer Institute
Collaborating Sponsors:
Boston Medical Center
National Cancer Institute (NCI)
Conditions:
Lung Cancer
Eligibility:
All Genders
21+ years
Phase:
PHASE2
Brief Summary
The purpose of this study is to develop and test the usability of a computerized symptom assessment and management intervention system in a laboratory setting (phase I) and its feasibility in a clinic...
Eligibility Criteria
Inclusion
- HCPs: attending physician, thoracic medical oncologist, expected to work in the setting for at least 2 years.
- Patients: 21 years of age or older; diagnosis of Stage IIIA, IIIB, IV non-small cell lung cancer OR limited or extensive stage small cell lung cancer; receiving care in the out-patient setting; receiving treatment with chemotherapy +/- additional therapies; English speaking.
Exclusion
- Patients: Any patient who needs emergent care, routine visits scheduled less than once a month
Key Trial Info
Start Date :
May 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2016
Estimated Enrollment :
179 Patients enrolled
Trial Details
Trial ID
NCT00852462
Start Date
May 1 2008
End Date
June 1 2016
Last Update
October 21 2016
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Dana-Farber Cancer Institute
Boston, Massachusetts, United States, 02115
2
Boston Medical Center
Boston, Massachusetts, United States, 02118